REVANCE THERAPEUTICS INC (RVNC)

US7613301099 - Common Stock

3.4  +0.11 (+3.34%)

After market: 3.4 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
77.8M
408.50%		132.6M
70.44%		234.04M
76.50%		287.35M
22.78%
EBITDA
YoY % growth
-254.85M
3.08%		-238.47M
6.43%		-209.35M
12.21%		-90.706M
56.67%
EBIT
YoY % growth
-274.7M
-0.55%		-272.2M
0.91%		-220.725M
18.91%		-161.42M
26.87%
Operating Margin
-353.08%-205.28%-94.31%-56.18%
EPS
YoY % growth
-4.18
13.53%		-3.94
5.74%		-3.79
3.81%		-2.35
38.10%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.77
-3.38%
Revenue
Q2Q % growth		57.766M
17.10%
EBITDA
Q2Q % growth		-16.32MN/AN/AN/AN/A
EBIT
Q2Q % growth		-70.153M
-20.89%		N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.62
34.74%		-0.740.1216.06%
Q3 2023
Q2Q % growth		 -1.63
-39.32%		-0.87-0.76-87.34%
Q2 2023
Q2Q % growth		 -0.80
9.09%		-0.79-0.01-0.84%
Q1 2023
Q2Q % growth		 -0.74
21.28%		-0.71-0.03-3.83%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 69.799M
39.82%		63.359M6.44M10.16%
Q3 2023
Q2Q % growth		 56.78M
95.66%		60.767M-3.987M-6.56%
Q2 2023
Q2Q % growth		 58.13M
104.90%		60.219M-2.089M-3.47%
Q1 2023
Q2Q % growth		 49.33M
95.29%		47.023M2.307M4.91%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -26.6% -2.6% -28.49%
Revenue0% -8.78% 0.21% -5.99%